MT1 and MT2 — Drug Target
All drugs that target MT1 and MT2 — marketed and clinical-stage. Includes 1 drug classes acting on this target.
Drug classes
Phase 3 pipeline (1)
- Rozerem (Ramelteon) · Southern California Institute for Research and Education · Melatonin receptor agonist · Sleep disorders
Rozerem (Ramelteon) is a melatonin receptor agonist that binds to melatonin receptors MT1 and MT2, mimicking the action of melatonin to regulate sleep-wake cycles.